Breaking: Pfizer Halts Diabetes Pill Trial Due to Alarming Side Effects | Redacted w Clayton Morris

Pfizer ended the clinical trial for a diabetes pill called lotiglipron because they say that it was leading to elevated enzymes in the liver. Pfizer says that it will instead focus on its obesity drug called danuglipron. That’s interesting because the obesity drug market is super hot right now. On Monday, Eli Lilly presented findings claiming that their obesity treatment could help people lose a quarter of their body weight in 11 months. Drug makers are rushing to compete with the viral popularity of Ozempic and Mounjaro. ✅ Sign up for our Free DAILY newsletter, delivered right to your inbox first thing in the morning. ➜ ✅ Become a Redacted Rebel VIP and get access to EXCLUSIVE content, live streams, and more! ➜ 👕 REDACTED MERCH 👕 Go grab some Redacted Merch from our store. Go to and pick some up. When you get it, send photos of you wearing it to photos@